
Supplements and Featured Publications
- Clinical Advance in the Management of Febrile Neutropenia
Erratum
In the October 2017 Perspectives in Febrile Neutropenia supplement to The American Journal of Managed Care®, Table 2 in the article entitled “Guidelines in the Management of Febrile Neutropenia for Clinical Practice” (page 11) misstated information regarding the Multinational Association of Supportive Care in Cancer (MASCC) febrile neutropenia risk index.
In the October 2017 Perspectives in Febrile Neutropenia supplement to The American Journal of Managed Care® (AJMC®), Table 2 in the article entitled “Guidelines in the Management of Febrile Neutropenia for Clinical Practice” (page 11) misstated information regarding the Multinational Association of Supportive Care in Cancer (MASCC) febrile neutropenia risk index.1 A MASCC risk index greater than 21 is low risk, not high risk. Additionally, a MASCC risk index less than or equal to 21 is high risk, not low risk. The table has been corrected on the
1. Klastersky J, de Naurois J, Rolston K, et al; ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118.
Articles in this issue
almost 8 years ago
Perspectives in Febrile Neutropenia: Q&A With Gary Lyman, MD, MPHalmost 8 years ago
The Relevance of Febrile Neutropenia in OncologyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.